Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivosidenib in IDH1-mutated Advanced Cholangiocarcinoma
NCT02989857Phase 3Completed
- Sponsor
- Servier
- Start
- Feb 2017
- Primary completion
- Jan 2019
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of ivosidenib in cholangiocarcinoma (CCA), sponsored by Servier. Started Feb 2017; status: completed.
02
Drugs
ivosidenib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT02989857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02989857.